U.S. Markets closed

CEL-SCI Corporation (CVM)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
2.66-0.14 (-5.00%)
At close: 3:59PM EDT

2.55 -0.11 (-4.14%)
After hours: 4:51PM EDT

People also watch
Full screen
Previous Close2.80
Bid2.54 x 1000
Ask3.00 x 2000
Day's Range2.57 - 2.83
52 Week Range0.06 - 3.69
Avg. Volume1,845,231
Market Cap24.79M
PE Ratio (TTM)-1.60
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1996-08-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com3 days ago

    Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

    The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

  • Associated Press8 days ago

    Cel-Sci reports 3Q loss

    On a per-share basis, the Vienna, Virginia-based company said it had a loss of 53 cents. The cancer immunotherapy company posted revenue of $17,400 in the period. Its adjusted revenue was $17,000. In the ...

  • CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017
    Capital Cube2 months ago

    CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017

    Categories: Yahoo FinanceGet free summary analysis CEL-SCI Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CEL-SCI Corp. – Curis, Inc., BioCryst Pharmaceuticals, Inc., Amgen Inc., Xencor, Inc., CytRx Corporation, Johnson & Johnson, Vical Incorporated, Teva Pharmaceutical Industries Limited Sponsored ADR and Emergent BioSolutions Inc. ... Read more (Read more...)